ResMed Inc (RMD)vsStevanato Group SpA (STVN)
RMD
ResMed Inc
$226.31
-0.82%
HEALTHCARE · Cap: $33.31B
STVN
Stevanato Group SpA
$14.18
-1.12%
HEALTHCARE · Cap: $3.91B
Smart Verdict
WallStSmart Research — data-driven comparison
ResMed Inc generates 355% more annual revenue ($5.40B vs $1.19B). RMD leads profitability with a 27.5% profit margin vs 11.8%. RMD appears more attractively valued with a PEG of 1.39. RMD earns a higher WallStSmart Score of 70/100 (B).
RMD
Strong Buy70
out of 100
Grade: B
STVN
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+14.4%
Fair Value
$303.30
Current Price
$226.31
$76.99 discount
Margin of Safety
-262.8%
Fair Value
$4.30
Current Price
$14.18
$9.88 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 35.2%
Safe zone — low bankruptcy risk
Every $100 of equity generates 26 in profit
Keeps 28 of every $100 in revenue as profit
Reasonable price relative to book value
Strong operational efficiency at 20.9%
Areas to Watch
No major concerns identified
4.8% revenue growth
0.3% earnings growth
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : RMD
The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.5% and operating margin at 35.2%. Revenue growth of 11.0% demonstrates continued momentum.
Bull Case : STVN
The strongest argument for STVN centers on Price/Book, Operating Margin.
Bear Case : RMD
No major red flags identified for RMD, but monitor valuation.
Bear Case : STVN
The primary concerns for STVN are Revenue Growth, EPS Growth, PEG Ratio.
Key Dynamics to Monitor
RMD profiles as a mature stock while STVN is a value play — different risk/reward profiles.
RMD carries more volatility with a beta of 0.89 — expect wider price swings.
RMD is growing revenue faster at 11.0% — sustainability is the question.
RMD generates stronger free cash flow (311M), providing more financial flexibility.
Bottom Line
RMD scores higher overall (70/100 vs 51/100), backed by strong 27.5% margins and 11.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ResMed Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.
Visit Website →Stevanato Group SpA
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Stevanato Group SpA (STVN) is a leading global provider of advanced drug delivery systems, specializing in integrated solutions tailored for the pharmaceutical and biotechnology sectors. The company excels in the design and manufacturing of glass and polymer packaging for injectable medications, improving efficiency and reliability in the drug delivery process. With a strong commitment to quality and sustainability, Stevanato is well-positioned to benefit from the growing biopharmaceutical market, making it an attractive prospect for institutional investors looking to invest in healthcare innovation and technology advancement.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?